Concerns About Pfizer Vaccine’s Link To Turbo Cancers

Mention the COVID-19 vaccine and the first name that usually comes to mind is the drug maker Pfizer. While once known for its block buster pills like Viagra and the statin Lipitor, Pfizer’s COVID-19 franchise now leads its profits from its vaccine, which made $37 billion in 2022, to its oral COVID-19 treatment Paxlovid, which made $18 billion in 2022.

You do not have to dig deep to find questions about Pfizer’s COVID-19 vaccine marketing tactics which FT (Financial Times) termed “The biggest marketing coup in history.”

“Unlike AstraZeneca and Johnson & Johnson, Pfizer never considered selling its Covid-19 shot without making a profit,” wrote the newspaper. Pfizer not only “controlled commercializing the vaccine in every country except the founders’ home territories of Germany and Turkey, and China,” its vaccine price in 2021 “was effectively four times the price of J&J’s single dose shot, and five times higher than a dose of AstraZeneca’s.”

Some former Pfizer employees and government officials with whom The Financial Times spoke questioned whether the COVID-19 vaccine balance of power had “tipped too far in Pfizer’s favor,” and Lawrence Gostin, a global health law professor at Georgetown University, expressed concerns that Pfizer was not “wielding their power fairly, openly, with a sense of compassion.”

Even Moncef Slaoui, who served as head of Operation Warp Speed, was shocked at Pfizer pricing and warned Pfizer CEO Albert Bourla, that the company could appear to be benefiting from a “once-in-a- century pandemic,” reported FT though his objections may have stemmed from the 155,000 shares of Moderna stock he owned. (More about the murky Operation Warp Speed and its military roots in a following article.)

Windfalls

Why has creating COVID-19 vaccine been so lucrative for drug makers? According to Dr. Joseph Mercola, the 1984 Bayh-Dole Act allows government scientists to make royalties from drug makers even though the government paid for the basic research. Yes, we taxpayers fund the government research and drug makers and NIH scientists keep all the profits in a double whammy to us.

Pfizer’s astonishing COVID-19 windfalls allowed the drug giant to recently move to The Spiral in New York City’s Hudson Yards, a swank edifice on 34th street between 10th Avenue and Hudson Boulevard East, where it will occupy 11 floors.

Safety Questions

Apparent profiteering on a “once-in-a- century pandemic” is hardly the only question swirling around Pfizer’s COVID-19 vaccine. While the public largely believed from health care messaging that the vaccine would prevent transmission of the virus, it didn’t. To get emergency approval, companies “did not have to show that the vaccine would also prevent people from spreading the virus to others,” reported Reuters and the revelation by Pfizer’s Janine Small at the EU parliament last fall that transmission was not even considered caused many to feel misled.

Last year, group of doctors including an editor at the medical journal BMJ wrote in ScienceDirect that Pfizer did not report serious adverse events that occurred more than one month after a patient’s second vaccine dose—even though such events include abscesses, pancreatitis, pneumothorax and psychosis. Then, Die Welt, a German news outlet, reported that data from trials of Pfizer’s COVID-19 vaccine Pfizer removed the occurrence of adverse events in subjects. Writer Igor Chudov described some of the adverse events on Substack.

No wonder, according to FT, Pfizer demanded that countries planning on using the COVID-19 vaccine “change their national laws to protect them from lawsuits.” Negotiations for South Africa to get the vaccine, for example, went poorly, but still Pfizer insisted “on indemnity against civil claims and required the government to provide finance for an indemnity fund.”

Why such a concern of liability for a safe vaccine?

More Safety Concerns

In 2019, both the American Cancer Society and the medical journal the Lancet reported that obesity-related cancers, including colorectal, uterine corpus, gallbladder, kidney, pancreatic cancers and multiple myeloma increasingly are being diagnosed in younger people.  And in 2022, during the pandemic, CNN confirmed that an epidemic of such “early onset” and aggressive cancers in young people is occurring. While the CNN article cited possible causative factors as obesity, inactivity, diabetes, alcohol, smoking, environmental pollution and Western diets high in red meat and added sugars, and sleep deprivation, the early onset cancer epidemic also coincides with mass vaccination for COVID-19 and should be considered a possibility.

Meanwhile, reports are surfacing about “turbo cancers” which are newly appearing cancers that seem to grow and spread very aggressively according to Dr. Charles Hoffe, a British Columbian family doctor. They are also very resistant to treatment, he says. “Cancer pathologists around the world have noticed this,” says Hoffe,”— people who have previous cancers which were in remission are flaring up since their shots because of the damage to their immune system” by the COVID-19 shots.”

Thomas Renz, a lawyer, also noted possible cancer/vaccine links from the military personnel database, Defense Medical Epidemiology Database (DMED). To wit: a nearly 900 percent increase in esophageal cancer and a 500 percent increase in breast and thyroid cancers after vaccine exposure.

Vaccine advocates like Dr. David H. Gorski discredit cancer/vaccine link claims including for “turbo cancers”—the “turbos” emanate from a “passive reporting system into which anyone can enter any adverse event after vaccination,” he says—but there is some evidence that the spike protein in the COVID-19 vaccine could affect the immune system.

Cancer links?

There are several reasons why few medical studies link receipt of the COVID-19 vaccine with cancers, much less “turbo” cancers. First, subjects with cancer are generally excluded from such trials and secondly, seldom do medical studies of those with COVID-19 include the subjects’ vaccine status. Many, after all, contracted the virus despite vaccination—even more than once.

Still, a paper published in the journal Viruses in 2021, raises thought provoking questions. Titled “SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro,” the paper postulates that the SARS–CoV–2 spike protein—which is in the vaccine as well— “significantly inhibits DNA damage repair, which is required for effective V(D)J recombination in adaptive immunity. Mechanistically, we found that the spike protein localizes in the nucleus and inhibits DNA damage repair by impeding key DNA repair protein BRCA1 and 53BP1 recruitment to the damage site. Our findings reveal a potential molecular mechanism by which the spike protein might impede adaptive immunity and underscore the potential side effects of full-length spike-based vaccines.”

What does the scientific language mean in plain English? The paper, like several practitioners who have gone on record, suggests the vaccine could affect the immune system and activate tumors and cancers. It casts into doubt the often-heard assurances from health agencies that the mRNA “does not enter the nucleus of the cell” and could not “inactivate the genes that suppress tumors.”

Since there is a chill today over scientific findings and clear censorship, the Swedish paper, titled “SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro,” written by researchers at the Wenner–Gren Institute at Stockholm University and at the Virology department at , Umeå University (also in Sweden) seems to constitute evidence of the cancer/vaccine links or even turbo vaccine reports that some are reporting.

A Significant Acquisition for Pfizer?

Pfizer’s COVID-19 windfalls have enabled it to indulge in a mergers and acquisitions spree. The drug maker paid $5.4 billion for Global Blood Therapeutics, a company developing rare blood disorder drugs and paid $11.6 billion for the complete acquisition of Biohaven, maker of an innovative migraine therapy which it had partially owned.

Yet Pfizer’s purchase of the cancer drug maker Seagen for $43 billion (“beefing up in oncology,” according to FiercePharma) may raise some eyebrows. Seagen describes itself as a “global biotechnology company dedicated to revolutionizing cancer care. We’re developing transformative therapies that make a meaningful difference in people’s lives.” If Pfizer’s COVID-19 vaccines are indeed accelerating cancers—even “turbo” cancers—such an acquisition would make a lot of business sense and could be an admission of the cancer link in the vaccine many are suspecting.

Related Posts